Editas posts Q4 net loss $45.4M ($0.55/sh); ends reni-cel, cuts 65% staff

Editas Medicine, Inc.

Q4 2024 net loss $45.4M vs $18.9M in Q4 2023; full-year net loss $237.1M vs $153.2M.
Cash $269.9M; operational runway into Q2 2027 includes $45-55M in restructuring costs.
Ended reni-cel development due to failed partnership search; workforce reduced ~65%.
On track to declare in vivo HSC and liver development candidates via gene upregulation mid-2025.
No future quarterly earnings conference calls.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.